Dr. Muin Khoury, founding director of the Office of Genomics and Precision Public Health at the Centers for Disease Control and Prevention, kicked off Day 2 by discussing how familial hypercholesterolemia (FH) sets the stage for precision public health for other inherited conditions and the progress we have made identifying and treating individuals with FH. Khoury underscored the importance of data for more precisely developing and delivering public health programs to sub-populations: “Families live across states and healthcare systems. We can’t do this without precision.”
Rear Admiral Betsy Thompson, head of the CDC’s Department of Heart Disease and Stroke prevention, underlined how FH and cholesterol are aligned with the strategic priorities of the CDC. Today, 39.1 million people in the U.S. are not using statins when indicated, according to NHANES data. It may be possible to prevent over 300,000 heart events per year just by increasing cholesterol management to 80% of those who are eligible for statins.
The “challenges and opportunities for integrating FH into state public health programs” were underscored by Deb Lochner Doyle’s talk. Opportunities for improvement currently being evaluated by the state of Washington include: - investigating population-based screening
- adding a state performance measure for lipid screening in 9 to 11-year-olds
- linking families at-risk to care via the “Cascade Screening Connector”
"Cascade screening is not happening very well in this country. Why not? Because it is very time consuming and no one pays for it. Perhaps this is a role for public health." – Debra Lochner Doyle, MS, LCGC | 
.png)
No hay comentarios:
Publicar un comentario